Valuation: Abivax

Market Cap 8.69B 10.02B 8.2B 7.44B 13.95B 961B 14.05B 97.89B 37.72B 487B 37.65B 36.82B 1,549B P/E 2026 *
-28.1x
P/E 2027 * -33.1x
Enterprise Value 7.59B 8.76B 7.16B 6.5B 12.19B 839B 12.27B 85.52B 32.95B 426B 32.89B 32.16B 1,354B EV / Sales 2026 *
108x
EV / Sales 2027 * 97.2x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day-1.63%
1 week+1.74%
Current month+2.15%
1 month-2.97%
3 months+17.17%
6 months-1.53%
Current year-17.23%
1 week 98.65
Extreme 98.65
105.1
1 month 95
Extreme 95
105.9
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 4.51
Extreme 4.51
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Exercice

Chief Executive Officer

17,728 0.0222%
7/11/26 Exercice

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
-1.63%+1.74%+40.95%+504.67% 10.25B
+0.56%-4.71%-2.45%+9.18% 45.48B
+0.66%-2.34%+340.62%+530.14% 43.68B
+1.49%-0.78%+41.90%+24.75% 43.09B
+2.11%-1.24%+9.09%+78.25% 39.4B
+0.34%-4.03%+9.34%+38.90% 31.91B
+0.53%-2.08% - - 17.31B
+1.34%+0.70%+21.35%+112.62% 16.4B
+2.07%+0.78%+13.07%+30.91% 14.24B
-1.85%-5.33%+78.63%+31.45% 13.28B
Average +0.56%-2.00%+61.39%+151.21% 27.5B
Weighted average by Cap. +0.84%-2.66%+74.61%+142.94%

Financials

2026 *2027 *
Net sales 70.18M 80.99M 66.23M 60.08M 113M 7.76B 114M 791M 305M 3.94B 304M 297M 12.52B 79.52M 91.77M 75.04M 68.08M 128M 8.8B 129M 896M 345M 4.46B 345M 337M 14.19B
Net income -265M -306M -250M -227M -426M -29.33B -429M -2.99B -1.15B -14.88B -1.15B -1.12B -47.3B -231M -266M -218M -198M -371M -25.52B -373M -2.6B -1B -12.95B -1B -978M -41.16B
Net Debt -1.1B -1.27B -1.04B -940M -1.76B -121B -1.78B -12.38B -4.77B -61.62B -4.76B -4.65B -196B -956M -1.1B -902M -819M -1.54B -106B -1.55B -10.78B -4.15B -53.65B -4.14B -4.05B -171B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-09-14 €99.65 -1.63% 81,653
26-09-11 €101.30 +1.00% 92,586
26-09-10 €100.30 -0.89% 92,399
26-09-09 €101.20 +0.20% 165,097
26-09-08 €101.00 +3.11% 120,091
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
99.65EUR
Average target price
137.98EUR
Spread / Average Target
+38.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!